Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients

doi:10.12998/wjcc.v11.i26.6105

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2650)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

115

WORD

HTML

1453

Figures (1-4)

236

Tables (1-4)

192

Sum=2018

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

144

Download

389

Sum=533

Sep 16, 2023 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Cases. Sep 16, 2023; 11(26): 6105-6121
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6105

Table 1 Antibodies candidate against severe acute respiratory syndrome coronavirus 2 under investigation by pharmaceutical companies

Antibody	Mechanism	Company	Stage of study/identification method
Canakinumab (ilaris^®)	IL-1β inhibitor	Novartis	In clinical stage for several inflammatory diseases including arthritis, periodic fever and lung cancer; repurposed by novartis for COVID-19
Secukinumab (cosentyx^®)	IL-17 inhibitor	Novartis	In clinical stage for several autoimmune diseases including psoriasis; repurpose by novartis for COVID-19
TZLS-501	Fully human monoclonal antibody targeting the receptor of IL-6, it binds to both membrane-bound and soluble forms of IL-6R, and rapidly depletes the circulating levels of IL-6 in blood	Tiziana Life Sciences and Novimmune	Preclinical stage
Pritumumab	Fully human IgG antibody targeting vimentin	Nascent Biotech Inc.	Received FDA approve for several carcinoma; Research began for COVID-19
COVID-HIG and COVID-EIG	Hyperimmune polyclonal antibody derived from human plasma or immunized horse	Emergent BioSolutions	Enter clinical trial within 4-5mo
Rcig	Recombinant anti SARS-CoV-2 hyperimmune gamma globulin, polyclonal antibodies	GigaGen	Preclinical stage-Aimed for COVID19 hospitalized patients and prophylaxis in high-risk individuals
Antibody cocktail including REGN3048-3051	Fully human multivalent antibodies against the spike protein isolated from genetically modified mice or recovered COVID-19 patients	Regeneron	Phase 1 clinical trial for Middle East Respiratory Syndrome completed last year; clinical trial for SARS-CoV-2 starts by early summer

IL: Interleukin; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; IgG: Immunoglobulin G; FDA: Food and Drug Administration.

Table 2 The Significance of differences in baseline characteristics between the three groups

Variables	Intervention
Variables	Casirivimab/Imdevimab (A)	Remdesivir (B)	Favipiravir (C)	P value^a
Age	58.34 ± 16.096	59.30 ± 15.985	65.02 ± 14.261	0.006
B and C				0.07
A and C				0.07
A and B				0.63
Gender				0.03
Male	24/53	42/106	61/106
Female	29/53	64/106	45/106
B and C				0.09
A and C				0.145
A and B				0.501
Number of co-morbidities				0.022
0	10/53	32/106	22/106
1	16/53	27/106	19/106
2	14/53	28/106	33/106
3	11/53	16/106	18/106
4	2/53	2/106	10/106
5	0/53	1/106	3/106
6	0/53	0/106	1/106
B and C				0.06
A and C				0.32
A and B				0.207
Method of diagnosis				1
Symptoms only	0/53	0/106	0/106
Labs and radiology	0/53	0/106	0/106
PCR confirmed	53/53	106/106	106/106
B and C				NA
A and C				NA
A and B				NA
Severity of COVID				0.024
Moderate	18/53	20/106	20/106
Sever	27/53	60/106	53/106
Critical	8/53	26/106	33/106
B and C				0.475
A and C				0.07
A and B				0.035
Number of symptoms				0.001
2	4/53	2/106	2/106
3	13/53	6/106	4/106
4	32/53	97/106	97/106
5	4/53	1/106	3/106
B and C				0.482
A and C				0
A and B				0.003
Antibiotics use				1
Yes	53/53	106/106	106/106
No	0/53	0/106	0/106
B and C				0.102
A and C				0.002
A and B				0.075
Macrolide use				0.007
Yes	8/53	8/106	2/106
No	45/53	98/106	104/106
B and C				0.102
A and C				0.002
A and B				0.075
Fluroquinolones use				0.106
Yes	41/53	92/106	95/106
No	12/53	14/106	11/106
B and C				NA
A and C				NA
A and B				NA
3^rd and 4^th generation cephalosporin use				0.551
Yes	39/53	86/106	83/106
No	14/53	20/106	23/106
B and C				NA
A and C				NA
A and B				NA
Carbapenems use				0.168
Yes	10/53	32/106	22/106
No	43/53	74/106	84/106
B and C				NA
A and C				NA
A and B				NA
Piperacillin/tazobactam use				1
Yes	0/53	0/106	0/106
No	53/53	106/106	106/106
B and C				NA
A and C				NA
A and B				NA
Amoxicillin/clavulanate use				0.472
Yes	0/53	0/106	0/106
No	53/53	106/106	106/106
B and C				NA
A and C				NA
A and B				NA
Cotrimoxazole use				1
Yes	0/53	0/106	0/106
No	53/53	106/106	106/106
B and C				NA
A and C				NA
A and B				NA
Linezolid use				0.115
Yes	5/53	12/106	4/106
No	48/53	94/106	102/106
B and C				NA
A and C				NA
A and B				NA
Teicoplanin use				0.365
Yes	1/53	0/106	2/106
No	52/53	106/106	104/106
B and C				NA
A and C				NA
A and B				NA
Anticoagulant use				0.411
Yes	49/53	101/106	96/106
No	4/53	5/106	10/106
B and C				NA
A and C				NA
A and B				NA
Dose of anticoagulant				0.088
Prophylactic	39/53	80/106	81/106
Therapeutic	14/53	26/106	25/106
B and C				NA
A and C				NA
A and B				NA
Antiplatelet use				0.012
Yes	5/53	6/106	0
No	48/53	100/106	106/106
B and C				0.039
A and C				0.005
A and B				0.262
Steroids use				0.002
Yes	45/53	105/106	98/106
No	8/53	1/106	8/106
B and C				0.5
A and C				0.068
A and B				0.001
Additive-therapy use				0.104
Yes	51/53	106/106	105/106
No	2/53	0/106	1/106
B and C				NA
A and C				NA
A and B				NA
Paracetamol use				0.019
Yes	50/53	105/106	106/106
No	3/53	1/106	0/106
B and C				0.574
A and C				0.006
A and B				0.022
Zinc use				0.003
Yes	4/53	0/106	1/106
No	49/53	106/106	105/106
B and C				0.614
A and C				0.004
A and B				0.001
Acetyl cysteine use				0.135
Yes	52/53	106/106	106/106
No	1/53	0/106	0/106
B and C				NA
A and C				NA
A and B				NA
Lactoferrin use				0.135
Yes	1/53	0/106	0/106
No	52/53	106/106	106/106
B and C				NA
A and C				NA
A and B				NA
Vitamin C use				0.07
Yes	4/53	7/106	1/106
No	49/53	99/106	105/106
B and C				NA
A and C				NA
A and B				NA
O₂ therapy use				0
Yes	37/53	99/106	102/106
No	16/53	7/106	4/106
B and C				0.497
A and C				0
A and B				0
NP use				0.84
Yes	18/53	35/106	39/106
No	35/53	71/106	67/106
B and C				NA
A and C				NA
A and B				NA
SFM use				0.002
Yes	30/53	82/106	87/106
No	23/53	24/106	19/106
B and C				0.428
A and C				0
A and B				0.004
MR use				0.003
Yes	8/53	33/106	14/106
No	45/53	73/106	92/106
B and C				0.001
A and C				0.783
A and B				0.019
HFNC use				0.202
Yes	5/53	22/106	18/106
No	48/53	84/106	88/106
B and C				NA
A and C				NA
A and B				NA
CPAP use				0
Yes	4/53	39/106	36/106
No	49/53	67/106	70/106
B and C				0.635
A and C				0.001
A and B				0
IMV use				0
Yes	1/53	29/106	29/106
No	52/53	77/106	77/106
B and C				1
A and C				0
A and B				0
Vasopressor use				0.002
Yes	0/53	23/106	18/106
No	53/53	83/106	88/106
B and C				1
A and C				0.016
A and B				0.001
Prone positioning				0.75
Yes	0/53	5/106	9/106
No	53/53	101/106	97/106
B and C				NA
A and C				NA
A and B				NA
O₂ saturation on O₂ therapy	96.26 ± 2.391	95.86 ± 3.795	96.01 ± 3.130	0.942
B and C				NA
A and C				NA
A and B				NA
O₂ saturation on RA	92.36 ± 4.816	87.62 ± 7.171	88.35 ± 7.006	0
B and C				0.448
A and C				0
A and B				0
PaO₂	77.868 ± 41.79	56.432 ± 35.30	63.294 ± 39.45	0.005
B and C				0.252
A and C				0.2
A and B				0.001
PaCO₂	36.689 ± 12.59	37.325 ± 14.60	37.603 ± 12.08	0.891
B and C				NA
A and C				NA
A and B				NA
PaO₂/FiO₂	233.5057 ± 207	156.7358 ± 171	164.142 ± 138	0.01
B and C				0.136
A and C				0.69
A and B				0.002

^aP < 0.05 is considered a statistically significant difference between the compared groups. (1) Comparing between the three groups (A, B, C); (2) A pairwise comparison between every 2 groups (A-B, B-C, A-C), if there is a statistically significant difference between the three groups as presented by the comparing between the three groups (A, B, C). NA: Not available; NP: Nasal prongs; SPM: Simple face mask; MR: Mask reservoir; RA: Room air; PCR: Polymerase chain reaction; HFNC: High-flow nasal cannula; COVID: Coronavirus disease; CPAP: Continuous airway positive pressure; IMV: Invasive mechanical ventilation.

Table 3 The best regression model for studying effects of confounding variables on need for invasive mechanical ventilation

	Unstandardized coefficients		Standardized coefficients		t-value	P value
	B	Std. Error	Beta	Std. Error	t-value	P value
(Constant)	0.806	1.297			0.621	0.535
Age	0.003	0.001	0.098	0.053	1.835	0.068
Gender	0.029	0.044	0.038	0.058	0.652	0.515
No of co-morbidities	-0	0.015	-0.01	0.048	-0.144	0.885
Severity of COVID	-0	0.036	-0.01	0.059	-0.123	0.903
No of symptoms	0.029	0.033	0.049	0.057	0.854	0.394
Macrolide	-0.03	0.083	-0.03	0.074	-0.362	0.718
Fluroquinolones	0.001	0.068	0.001	0.073	0.02	0.984
Cephalosporin	0.046	0.071	0.052	0.081	0.646	0.519
Carbapenems	0.057	0.07	0.065	0.08	0.818	0.415
Amox/calv	-0.19	0.398	-0.02	0.039	-0.479	0.632
Linezolid	-0.01	0.072	-0.01	0.058	-0.097	0.923
Teicoplanin	-0.2	0.316	-0.03	0.044	-0.636	0.526
Other Antibiotics	-0.03	0.105	-0.01	0.043	-0.274	0.784
Anticoagulant	-0.1	0.099	-0.07	0.067	-1.033	0.303
Prophylaxis/therapeutic	-0.01	0.048	-0.02	0.063	-0.298	0.766
Antiplatelet	-0.03	0.083	-0.02	0.06	-0.34	0.734
Steroids	-0.04	0.078	-0.04	0.065	-0.561	0.576
Additive therapy	0.096	0.12	0.041	0.051	0.803	0.423
Paracetamol	-0.05	0.095	-0.02	0.05	-0.475	0.635
Zinc	-0.1	0.084	-0.06	0.049	-1.21	0.228
Acetylcysteine	-0.03	0.176	-0.01	0.052	-0.151	0.88
Lactoferrin	0.312	0.237	0.092	0.07	1.315	0.19
Vitamin C	0.044	0.072	0.031	0.05	0.615	0.539
Nasal prongs use	-0	0.043	-0.01	0.055	-0.083	0.934
FM use	0.04	0.053	0.046	0.06	0.764	0.446
MR use	-0.03	0.05	-0.03	0.054	-0.538	0.591
HFNC use	0.004	0.05	0.003	0.048	0.071	0.944
CPAP	0.003	0.092	0.004	0.101	0.035	0.972
vasopressor	0.054	0.093	0.042	0.072	0.579	0.563
Prone position	-0.18	0.105	-0.08	0.046	-1.74	0.084
PaO₂	-0	0.001	-0.19	0.067	-2.841	0.005
PaCO₂	-0.01	0.002	-0.15	0.052	-2.852	0.005
PaO₂/Fio₂	0.001	0	0.175	0.065	2.695	0.008

P < 0.05 mean the baseline characteristic does not affect the study outcomes; P ≥ 0.05 mean the baseline characteristic can affect the study outcomes. COVID: Coronavirus disease; FM: Face mask; MR: Mask reservoirs; HFNC: High-flow nasal cannula; CPAP: Continuous airway positive pressure.

Table 4 The Significance of differences in baseline characteristics between the three groups

Variables	Intervention
Variables	Casirivimab/Imdevimab(A)	Remdesivir (B)	Favipiravir (C)	P value^a
PaO₂/FiO₂ on day 3	298.57 ± 211.3	154.14 ± 138.9	166.96 ± 130	0
B and C				0.478
A and C				0
A and B				0
PaO₂/FiO₂ on day 7	320.62 ± 93.64	163.55 ± 172.6	178.59 ± 138	0
B and C				0.413
A and C				0
A and B				0
PaO₂/FiO₂ on day 14	389.75 ± 51.93	154.67 ± 174	165.2 ± 98.87	0.005
B and C				0.155
A and C				0.022
A and B				0.001
PaO₂/FiO₂ on day 28		172.75 ± 181	53 ± 0	0.48
B and C				NA
Need for IMV				0.005
Yes	1/53	22/106	22/106
No	52/53	84/106	84/106
B and C				1
A and C				0.003
A and B				0.003
Duration of need for O₂ therapy and IMV	3.72 ± 3.527	9.2 ± 7.107	7.46 ± 5.077	0
B and C				0.119
A and C				0
A and B				0

Citation: Hegazy SK, Tharwat S, Hassan AH. Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients. World J Clin Cases 2023; 11(26): 6105-6121
URL: https://www.wjgnet.com/2307-8960/full/v11/i26/6105.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i26.6105